WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Three-Drug attack on rare blood cancer begins human testing
Disease control Not yet recruitingThis study is testing whether adding a new oral drug called nemtabrutinib to two existing medications (bortezomib and rituximab) works better for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. The trial will enroll 19 adults in South Korea who have ne…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug duo aims to control tough blood cancer
Disease control Not yet recruitingThis study is testing a combination of two oral drugs, zanubrutinib and BGB-11417, for adults whose Waldenström macroglobulinemia (a rare blood cancer) has come back or stopped responding to prior treatment. The goal is to see if this time-limited, 20-cycle treatment can achieve …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Experimental drug targets tough blood cancers in early safety trial
Disease control Not yet recruitingThis early-stage trial is testing a new drug called LY4152199 in people with B-cell lymphomas that have returned or didn't respond to previous treatments. The main goals are to find a safe dose and see if the drug shows any signs of helping control the cancer. The study will enro…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC